Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 07-oct-2026 · last seen 07-oct-2026

Vibegron (GEMTESA)

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-09-29 — Vibegron for ENergy Thinking and Resilience in Aging: 12-week randomized, double-blind, placebo-controlled trial (VENTURA-Aging) launched to test vibegron (a β3-adrenergic agonist approved for overactive bladder) for energy metabolism, cardiometabolic risk, and physical/cognitive function in middle-aged and older adults with obesity — trial registered, no results yet. [human-rct] (novelty: 3)

Open questions

Related

Contributing findings

clinicaltrials trial early human-rct
Vibegron for ENergy Thinking and Resilience in Aging
29-sep-2026 novelty 3 per-area 3 strengthens

build build 880 · 2bcef25 · 2026-11-18